New drug duo targets Hard-to-Treat breast cancer
NCT ID NCT07597629
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two drugs together for people with advanced breast cancer that cannot be removed by surgery. SYS6023 targets a protein called HER3 on cancer cells, while KN026 targets HER2. The goal is to see if the combination is safe and shrinks tumors. About 36 adults with confirmed HER3-positive breast cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYS6023 (a drug that targets HER3 on cancer cells) and KN026 (a drug that targets HER2 on cancer cells)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced breast cancer that has not responded to other therapies.
What could go wrong
This is an early Phase II trial with only 36 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Tumor Hospital of Harbin
RECRUITINGHarbin, Heilonjiang, 150000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••